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Low- and middle-income countries 
A B S T R A C T   
Objectives: The prevalence of all epilepsies (both convulsive and non-convulsive seizures) in Low- and Middle- 
Income Countries (LMIC), particularly sub-Saharan Africa is unknown. Under estimation of non-convulsive ep-
ilepsies in data from these countries may lead to inadequate and sub-optimal allocation of resources to control 
and prevent epilepsy. We determined the prevalence of all types of epilepsies and compared the mortality be-
tween convulsive seizures and non-convulsive seizures in a resource limited rural area in Kenya. 
Methods: Trained clinicians identified cases of epilepsy in a randomly selected sample of 4,441 residents in the 
Kilifi Health and Demographic Surveillance System site using a cross-sectional survey design. Seizure types were 
classified by epileptologists using the current guidelines of the International League Against Epilepsy (ILAE). We 
estimated prevalence for epilepsy with convulsive seizures and non-convulsive seizures and for epilepsy with 
non-convulsive seizures only and compared premature mortality between these groups of seizures. 
Results: Of the 4441 people visited, 141 had lifetime epilepsy and 96 active epilepsy, which is a crude prevalence 
of 31.7/1,000 persons (95% CI: 26.6-36.9) and 21.6/1,000 (95% CI: 17.3-25.9), respectively. Both convulsive 
and non-convulsive seizures occurred in 7% people with epilepsy (PWE), only convulsive seizures in 52% and 
only non-convulsive seizures in 35% PWE; there was insufficient information to classify epilepsy in the 
remainder 6%. The age- and sex-adjusted prevalence of lifetime people was 23.5/1,000 (95% CI: 11.0-36.0), with 
the adjusted prevalence of epilepsy with non-convulsive seizures only estimated at 8.2/1,000 (95%CI:3.9-12.6). 
The mortality rate in PWE was 6.3/1,000 (95%CI: 3.4-11.8), compared to 2.8/1,000 (2.3-3.3) in those without 
epilepsy; hazard ratio (HR) =2.31 (1.22-4.39; p=0.011). The annual mortality rate was 11.2/1,000 (95%CI: 5.3- 
23.4) in PWE with convulsive and non-convulsive seizures and none died in PWE with non-convulsive seizures 
alone. 
Conclusions: Our study shows that epilepsy with non-convulsive seizures is common and adds to the prevalence of 
previously reported estimates of active convulsive epilepsy. Both epilepsy with convulsive seizures and that with 
non-convulsive seizures should be identified for optimising treatment and for planning resource allocation.   
1. Introduction 
Epilepsy is one of the most common chronic neurological disorders 
and is an important public health problem affecting close to 70 million 
people worldwide [1]. This number approximates about 0.7% of the 
global burden of disease and contributes up to 17 million disability 
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adjusted life-years (DALYs) annually [2]. Up to 90% of the people with 
epilepsy (PWE) reside in low and middle income countries (LMICs) [1], 
with 20% of the global burden in Africa alone [3]. Another 500 million 
people are affected indirectly as parents, relatives and friends [4]. 
Proximate causes, features and consequences of epilepsy with convul-
sive seizures have been described [5], but these have not been system-
atically studied for epilepsy with non-convulsive seizures in LMIC. 
Most epidemiological studies in Africa have focused on epilepsy with 
convulsive seizures, since these seizures are easier to detect in cross- 
sectional surveys and are thought to be associated with more 
morbidity and premature mortality [6]. Non-convulsive seizures are 
more difficult to detect, and often need experienced clinicians to elicit 
the subtle manifestations. Two previous studies have estimated crude 
prevalence of epilepsy with convulsive and of epilepsy with 
non-convulsive seizures at 10.2/1,000 and 12.5/1,000, in Kenya and 
Zambia respectively [7,8]. Neither study used experienced clinicians to 
screen the populations, and both noted the limitations of their studies to 
identify non-convulsive seizures. Furthermore, neither study estimated 
the prevalence of life-time epilepsy. 
Cross-sectional studies are thought to underestimate the prevalence 
of life-time epilepsy since non-convulsive seizures are difficult to detect 
and may constitute up to 50% of all epilepsies in population-based 
studies [9]. This preponderance of studies of epilepsies with convul-
sive seizures is primarily due to scarcity of resources and manpower for 
detecting non-convulsive seizures, which may occur in 17-50% of all 
epilepsies [9,10]. The paucity of epidemiological data on epilepsy with 
non-convulsive seizures underestimates the true burden of epilepsy in 
LMIC, complicates comparison of estimates with those from the 
high-income countries (HIC) and affects planning and allocation of re-
sources for epilepsy care. 
A number of cross-sectional surveys to determine the prevalence of 
active convulsive epilepsy have been conducted in the Kilifi Health and 
Demographic Surveillance System (KHDSS) study area in Kenya (http:// 
www.kemri-wellcome.org/khdss/). Two small surveys estimated prev-
alence at 4.0/1,000 using a combination of one round survey and key- 
informants [11] and 11/1,000 in children aged 6–9 years using a two 
round survey [12]. A more recent three-stage prevalence survey esti-
mated the prevalence of active convulsive-epilepsy at 7.8/1,000 after 
adjusting for attrition-between stages and sensitivity of the screening 
methodology [13]. 
We conducted a cross-sectional survey to estimate the prevalence of 
epilepsy with convulsive seizures and that with non-convulsive seizures 
in a randomly selected sample of the KHDSS population in in which the 
population was screened by clinical officers who had been trained in the 
diagnosis of epilepsy. We further classified the seizure types that char-
acterize the identified cases and followed-up the sample to assess pre-
mature mortality. 
2. Methods and materials 
2.1. Study setting 
We conducted the study within the KHDSS (http://www.kemri- 
wellcome.org/khdss/) which covers an area of 891 km2. It is located 
in Kilifi District, one of the poorest districts in Kenya comprising of a 
population of 233,880 persons in 2008 living in 25,526 homesteads 
[14]. The KHDSS area was mapped using global positioning system 
(GPS) receivers, and digital maps derived from these data were used to 
locate homesteads and follow up study participants. Community based 
field workers conduct re-enumeration and vital status registration to 
update the population registers by visiting every homestead two or three 
times per year. The population is served by the Kilifi County Hospital, 
which is located at the centre of the KHDSS area. The main causes of 
paediatric admissions to hospital are neonatal insults, infections of the 
brain and head injury [13,15], which may be important risk factors for 
epilepsy in this area. 
Residents of the study area are Mijikenda, which is a Bantu grouping 
of nine tribes with Girima (45%), Chonyi (33%) and Kauma (11%) being 
the most common. About 55% of the population is considered absolutely 
poor with per capita monthly income of about 10 USD. The majority 
(80%) depend on subsistence farming, which is constrained by the low 
agricultural potential of the land (only 19% is arable). Only 45% of 
people are literate. During the years of the study, crude birth and death 
rates for this area are approximately 35/1,000 and 6/1,000 per year 
respectively, and migration rates are approximately 100/1,000 per year, 
most of which is within the study area [14]. 
2.2. Study population and cross-sectional survey 
Using a prevalence estimate of 4.5/1,000 [13,16] we estimated that 
a minimum sample size of 3,263 people was required to determine the 
prevalence of all types of epilepsies in Kilifi [17,18]. To account for loss 
to follow-up and meet the sample size requirements for an embedded 
validation study [19], a sample of 5,796 people resident in the study 
area was randomly selected from the 2008 KHDSS census database for 
this study. 
The study clinicians (experienced in the diagnosis and management 
of epilepsy) visited the homes of 5,796 people randomly chosen from the 
KHDSS database, to recruit them into the study. The clinicians per-
formed a detailed clinical history to identify PWE among those found at 
home (numbers shown in Fig. 1). Epilepsy was defined as two or more 
unprovoked seizures in a life-time where least 2 of the seizures occurred 
≥ 24 hours apart [20,21]. After the field survey, all case notes were 
reviewed independently by two neurologists (CRN and BN) to confirm 
the diagnoses assigned by the study clinicians. Psychogenic 
non-epileptic seizures and syncope were excluded on the clinical history, 
since further investigations such as electrocardiogram (ECG) and vid-
eo/EEG telemetry were not possible in the field. Psychogenic 
non-epileptic seizures were suspected if the person resisted attempts to 
restraint limb movement, forcefully closed eyes during the entire 
seizure, or had an event only in public, and never when alone. Syncope 
was suspected if, for example, the seizures were due to prolonged 
standing in hot crowded places, or if there was rapid recovery from the 
seizure without post-ictal confusion or drowsiness. 
The two neurologists also classified seizure types from available 
data, using the recommendations of the Commission of the Classification 
and Terminology of the ILAE. The seizure semiology information was 
used to categorize epilepsy into: (i) epilepsy with convulsive seizures, 
which included non-convulsive seizures; and (ii) epilepsy with non- 
convulsive seizures, which excluded convulsive seizures. This study 
was conducted during the period 2nd May 2009 to 30th April 2011, and 
the people with epilepsy were followed four-monthly for mortality sta-
tus until 31st December 2020. 
Fig. 1. Follow-up of participants in the cross-sectional survey  
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2.3. Analysis 
All data were double entered and verified in MySQL Version 5 open- 
source database (Oracle Corporation, Redwood Shores, CA, USA). 
Prevalence of all epilepsies was estimated as the number confirmed to 
have epilepsy divided by the number interviewed and expressed per 
1000 persons with 95% confidence intervals (CI). Prevalence was esti-
mated by age and sex and for epilepsies with convulsive seizures plus 
non-convulsive seizures and for those with non-convulsive seizures 
alone. Exploratory comparison of frequencies was done with Pearson’s 
Chi-squared test (X2) or Fisher’s exact test (when observations were 
infrequent). Mortality rate was computed as a function of number of 
deaths divided by person years of observation. All analyses were per-
formed in STATA version 15 (StataCorp, College Station, TX, USA). 
2.4. Ethical considerations 
Written informed consent was obtained from all study participants. 
Approval for the study was obtained from the Kenya Medical Research 
Institute/ National Ethical Review Committee. 
3. Results 
3.1. Follow-up of participants 
Out of the random sample of 5,796 participants, 1355 (23.4%) were 
could not be identified: 629 (46.4%) had moved, 534 (39.4%) could not 
be traced, 119 (8.8%) refused consent and 70 (5.2%) had died, while 3 
(0.2%) were found to have been duplicate records (Fig. 1). Among the 
4,441 found (Table 1), 53.5% were females. The attrition from the 
cohort did not vary by age (P=0.1) or sex (P=0.9). 
3.2. Prevalence of life-time epilepsy and active epilepsy 
A total of 141 people reported a history of at least 2 unprovoked 
seizures yielding a crude life-time prevalence of 31.7/1,000 persons 
(95% CI: 26.6-36.9). The prevalence of lifetime epilepsy was 31.6/1,000 
(95% CI: 24.5-38.6) in females and was 32.0 (95% CI: 24.4-39.6) in 
males, being similar between the sexes (P=0.936). The prevalence of 
lifetime epilepsy did not vary significantly by age (P=0.136), although it 
was lowest in the youngest (0-5 year) age group (21.6 per 1,000 (95%CI: 
12.0-31.2)) and highest in oldest age-group (50+ years) (49.4 (95%CI: 
28.7-70.1)) (Table 1). Age- and sex-adjusted prevalence of lifetime ep-
ilepsy was 23.5/1,000 (95% CI: 11.0-36.0). 
Ninety-six (96) reported at least one unprovoked seizure in the 12 
months preceding the survey, a crude prevalence of 21.6/1,000 (95% CI: 
17.3-25.9) for active epilepsy. The prevalence of active epilepsy was 
21.8/1,000 (95% CI: 16.00-27.7) in females and was 21.3/1,000 (95% 
CI: 15.1-27.6) in males, being similar between the sexes (P=0.898). The 
prevalence of active epilepsy did not vary significantly by age-group 
(P=0.260), although it was lowest in the young adults (19-28 year) 
age-group (14.7 per 1,000 (95%CI: 5.2-24.3)) and highest in oldest age- 
group (50+ years) (32.9 (95%CI: 15.9-50.9)) (Table 1). Age- and sex- 
adjusted prevalence of active epilepsy was 16.0/1,000 (95% CI: 5.6- 
326.4). 
3.3. Seizure semiology 
Of the 141 people with epilepsy, seizure semiology could be accu-
rately determined in 83/141 (58.9%). Convulsive seizures were detected 
in 59% and non-convulsive seizures in 42% people with epilepsy. Both 
convulsive and non-convulsive seizures occurred in 7% PWE, only 
convulsive seizures in 52% and only non-convulsive seizures in 35% 
PWE (Table 2). Distribution of specific seizures types defining convul-
sive or non-convulsive seizures are shown in Table 2. Seizures were 
unspecified in 6%, in whom it was difficult to determine whether they 
were convulsive or non-convulsive (Table 2). Given the proportion of 
non-convulsive seizures only of 35%, the minimum prevalence of life-
time epilepsy with non-convulsive seizures was 11.1/1,000 persons 
(95% CI: 9.31-12.92) based on crude estimates and was 8.2/1,000 
persons (95%CI:3.9-12.6) when based on adjusted estimates. Focal sei-
zures comprised 68% of all epilepsies. 
3.4. Mortality associated with epilepsies with convulsive or non- 
convulsive seizures 
Of the 4,441 people in whom epilepsy status was determined, 146 
died (Table 3), which is an annual mortality rate of 2.9 per 1,000 pop-
ulation (95%CI: 2.4-3.4). Of the 146 deaths, 9/96 (9.4%) occurred in 
those with active epilepsy, being greater than in those without epilepsy 
(137/4,344 (3.2%); X2 P=0.001), and similar with those with inactive 
epilepsy (1/45 (2.2%); Fisher’s exact P=0.169). The mortality rate in 
those with lifetime epilepsy was 6.4/1,000/year (95%CI: 3.41-11.80), 
while it was 2.8/1,000/year (2.3-3.2) in those without epilepsy; haz-
ard ratio (HR) =2.31 (1.22-4.39; p=0.011). 
The mortality rate in active epilepsy appeared greater than in inac-
tive epilepsy (Table 3), but the difference did not reach significance 
levels (HR=4.41 (95%CI: 0.56-34.85; p=0.159)). The mortality rate was 
(11.2/1,000/year (95%CI: 5.3-23.4)) in those with epilepsy with 
Table 1 
Prevalence (per 1,000 persons) of active and life-time epilepsy in Kilifi, Kenya.      
Life-time epilepsy Active epilepsy 
Age group Males:N=2,064 FemalesN=2,377 All: N=4,441 Cases: N=141 Prevalence per 1,000 (95% CI) Cases: N=96 Prevalence per 1,000 (95% CI) 
0-5 439 442 881 19 21.56 (11.95-31.17) 13 14.75 (6.77-22.73) 
6-12 521 560 1,081 39 36.07 (24.94-47.21) 26 24.05 (14.90-33.19) 
13-18 378 320 698 23 32.95 (19.67-46.22) 17 24.35 12.89-35.81) 
19-28 309 302 611 18 29.45 (16.01-42.90) 9 14.73 (5.15-24.30) 
29-49 255 490 745 21 28.18 (16.27-40.10) 17 22.81 (12.07-33.56) 
+50 162 263 425 21 49.41 (28.72-70.09) 14 32.94 (15.90-49.97)  
Table 2 
Classification of seizure types in people with life-time epilepsy in Kilifi, Kenya.  
Seizure type Cases with seizure 
semiology: N=83 (%) 
Convulsive seizures only 43 (51.8%) 
Generalised tonic-clonic seizures 10 
Generalised other motor seizures 3 
Focal to bilateral tonic-clonic seizures 7 
Focal motor seizures 18 
Other motor seizures eg myoclonic 5 
All convulsive seizures (including cases with 
convulsive and non-convulsive seizures) 
49 (59.0%) 
Both convulsive and non-convulsive seizures 6 (7.2%) 
Non-convulsive seizures only 29 (34.9%) 
Generalized absence seizures 8 
Focal impaired awareness seizures 19 
Focal sensory seizures 3 
All non-convulsive seizures (including cases with non- 
convulsive and convulsive seizures) 
35 (42.1%) 
Unspecified seizures 5 (6.0%) 
Generalized unspecified seizures 1 
Focal unspecified seizures 4  
S.M. Kariuki et al.                                                                                                                                                                                                                              
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on July 13, 
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
Seizure: European Journal of Epilepsy 89 (2021) 51–55
54
convulsive and non-convulsive seizures, while none died in those with 
epilepsy with non-convulsive seizures only (Table 3) (Fisher’s exact 
P=0.134). 
4. Discussion 
This is the first study in sub-Saharan African to provide an estimate of 
the prevalence of lifetime and active epilepsy prevalence of both epi-
lepsy with convulsive seizures and non-convulsive seizures, and epilepsy 
with non-convulsive seizures only in a rural setting. The overall age and 
sex adjusted prevalence was 23.5/1,000 (95%CI: 11.0-36.0) and did not 
differ by sex and age groups, an estimate that is greater than for 
convulsive epilepsies from similar settings [13]. Active epilepsy was 
common, with the adjusted prevalence being 16.0/1,000 (95% CI: 
5.7-326.4), with no differences between sex and age-groups; active ep-
ilepsies are easier to recall in the past one year and are the basis for 
starting anti-seizure medications in Kenya. Convulsive seizures only 
were reported by more people (52%), than non-convulsive seizures only 
were (35%), expectedly because the former seizures are easier to detect. 
Most of these seizures had a focal onset (68%), but it is possible some of 
these would evolve into generalized seizures under electroencephalog-
raphy. Adjusted prevalence of epilepsy with non-convulsive seizures 
only was estimated as 8.23/1,000 persons; these seizures would easily 
be confused for mental health symptoms and would go untreated if not 
identified. 
The age-adjusted prevalence of all epilepsies of 23.5/1,000 is three 
times that of active convulsive epilepsy reported in a study from the 
same area (7.1/1,000) [13], suggesting estimates based on active 
convulsive epilepsy only grossly underestimate the true prevalence by at 
least 70%, consistent with suggestions by other authors [7]. The con-
servative adjusted prevalence of non-convulsive epilepsies of 8.2/1,000 
is two times greater than that reported in developed countries (4/1,000) 
[22], where there is capacity to identify non-convulsive epilepsies. In 
our study some seizures could not be specified into either convulsive or 
non-convulsive seizures due to limited information provided by pa-
tients, which may have underestimated the proportion used to estimate 
prevalence. The presence of seizure susceptibility genes in this popula-
tion [23] and the increased incidence of risk factors such as central 
nervous system infections [13] explains the high prevalence of epilepsy 
in resource poor countries compared to developed countries. There are 
no lifetime estimates for non-convulsive epilepsies in SSA to compare 
with since the few epidemiological studies that attempted to include 
non-convulsive seizures focused on the prevalence of active epilepsy 
only [7,8], the definitions for active epilepsy in these two studies was for 
seizures in the last 2 or 5 years, unlike our study where seizures in the 
last year were considered. 
Our active epilepsy estimate (16.0/1,000 (95%CI: 5.7-326.4) are 
substantially greater than those for other studies from Zambia (12.5/ 
1,000) [7] and Kenya (10.2/1,000) [8], despite the other two studies 
having used a less strict inclusion criteria of 2-5 years for active epilepsy 
that would allow in more epilepsies. The differences may also be related 
to the methodology used across the studies. For example, our study 
employed trained clinicians who may detect more people with 
non-convulsive seizures than lay fieldworkers would. As expected, our 
active epilepsy estimates are considerably greater than those of studies 
that did not include non-convulsive epilepsies e.g. studies from Bolivia 
(11.1/1,000), and China (4.6/1,000) [24]. Active epilepsy is the main 
criteria used to prescribe anti-epileptic drugs in Kenya, and therefore 
those with active non-convulsive seizures can benefit from treatment. 
Other resource limited settings should invest in the training and iden-
tification of non-convulsive seizures, some of which can be confused for 
mental health symptoms [25]. 
Focal seizures were more common than generalized seizures, similar 
to a study of active convulsive epilepsy in sub-Saharan Africa [5]. Focal 
seizures suggest symptomatic epilepsy with easily identifiable prevent-
able causes [26]. Unfortunately, during the study period EEG could not 
be performed on most people detected with seizures in the community. 
Seizures types are useful in choice of anti-seizure medications, and a 
proportion of patients with non-convulsive seizures may require 
anti-seizure medications such as ethosuximide or sodium valproate for 
absence seizures [27]. Some non-convulsive seizures e.g. absences can 
be exacerbated by first generation anti-seizure medications such as 
phenobarbital, that are widely used in LMIC [28,29]. The high propor-
tion of non-convulsive seizures may indicate childhood absence epilepsy 
or temporal lobe epilepsy are common in this area [30]. Temporal lobe 
epilepsy syndromes may be a consequence of acute seizures, 
malaria-associated seizures or status epilepticus, which are common in 
this area [31]. 
This study shows that mortality rate was significantly greater in 
epilepsy than in those without, which is similar to previous studies from 
this area [6]. The mortality rates are however lower than that reported 
in the Ngugi et al. study even when we considered active epilepsy only. 
This is likely due to methodological differences in these two studies, 
whereby follow-up in our study was done within the framework of de-
mographic surveillance system, which is done every four months and 
may miss some mortality cases. In the Ngugi et al. study, PWE were 
specifically and frequently followed by epilepsy fieldworkers, which 
may have increased the reporting of mortality. Secondly, our study 
followed up for a longer period, which increases the denominator person 
years of observations. Hazard ratios showed similar mortality for active 
and inactive epilepsy, suggesting that causes or risk factors of mortality 
are common to both epilepsy types. Mortality was greater in the epi-
lepsies with convulsive and non-convulsive seizures than with only 
non-convulsive seizures, probably because the former seizures are 
associated with causes of death such as drowning and accidents. 
Although stigma may be less in epilepsy with non-convulsive seizures 
and non-convulsive seizures than in that with convulsive seizures only, 
both seizures should be identified to optimise treatment. 
These estimates are reliable since the diagnosis of epilepsy was made 
by experienced epilepsy specialists using standard criteria [5, 21]. Use of 
clinicians trained in the diagnosis of epilepsy improved identification of 
epilepsy with non-convulsive seizures [19]. Some participants with ep-
ilepsy did not describe their seizures to the level of information that 
would have allowed classification into either epilepsy with convulsive 
seizures or that with non-convulsive seizures. Clinical history was used 
to differentiate psychogenic non-epileptic seizures or syncope from ep-
ilepsy since video telemetry and ECG were not performed in the field. 
However, the classification reported in the study is based on semiology 
only since we did not perform EEG and neuroimaging due to logistic 
reasons. Coroner’s autopsy reports were not available to conform causes 
of death, and cultural reasons in this rural community may have affected 
reporting of deaths. The passive method of follow-up which may not 
capture deaths in those who emigrated may have underestimated mor-
tality rates. 
Table 3 
Mortality rates in those with and without epilepsy.  
Condition PYO Number of 
deaths 
Mortality rate per 
1,000 per year 
All participants 50,967 146 2.9 (2.4-3.4) 
With epilepsy 1,574 10 6.4 (3.4-11.8) 
Without epilepsy 49,392 136 2.8 (2.3-3.3) 
Active epilepsy 1054 9 8.5 (4.4-16.4) 
Inactive epilepsy 520 1 2.0 (0.27-13.7) 
Epilepsy with convulsive seizures 
plus non-convulsive seizures 
626 7 11.1 (5.3-23.4) 
Epilepsy with non-convulsive 
seizures only 
384 0 0 
PYO=person years of observation 
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5. Conclusions 
The burden of all epilepsies in this area is higher than that of 
developed countries and suggests that local active convulsive epilepsy 
estimates grossly underestimate the overall prevalence of epilepsy. The 
high prevalence of all epilepsies may be related to the increase in the 
burden of risk factors for epilepsy in this area. Non-convulsive seizures 
add to the burden of active convulsive epilepsies that are considered the 
criterion for starting anti-seizure medications in Kenya and other LMIC 
settings. Although mortality is greater in epilepsy with convulsive sei-
zures plus non-convulsive seizures than that with non-convulsive sei-
zures only, stigma may be similar in both and should be addressed. 
Assessment by experienced clinicians is expensive, but is the most 
objective way of obtaining reliable data on epilepsy with non-convulsive 
seizures in LMIC. Future studies in similar settings using a common 
methodology are required to enable comparisons. 
Funding 
This study was supported by the Wellcome Trust, through a Senior 
Clinical Research Fellowship (083744 to CN). SMK is supported by MQ: 
Transforming Mental Health (MQF17-18Kariuki) and by the EDCTP2 
programme supported by the European Union (TMA2017CDF-1903). 
Both SMK and CN are supported by NIHR Research and Innovation for 
Global Health Transformation (RIGHT) programme . 
Declaration of Competing Interest 
None. 
Acknowledgements 
We thank Collins Kipkoech and Paul Mwangi for help with data 
management. This paper is published with permission from the Director 
of KEMRI. 
References 
[1] Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the 
burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010; 
51(5):883–90. 
[2] Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, 
Charlson FJ, Norman RE, Flaxman AD, Johns N, et al. Global burden of disease 
attributable to mental and substance use disorders: findings from the Global 
Burden of Disease Study. Lancet 2010;382(9904):1575–86. 2013. 
[3] World Bank: WDR. Making services work for people. World Bank; 2004. 2004. 
[4] Kale R. The treatment gap. Epilepsia 2002;43:31–3. 
[5] Kariuki SM, Matuja W, Akpalu A, Kakooza-Mwesige A, Chabi M, Wagner RG, 
Connor M, Chengo E, Ngugi AK, Odhiambo R, et al. Clinical features, proximate 
causes, and consequences of active convulsive epilepsy in Africa. Epilepsia 2013. 
[6] Ngugi AK, Bottomley C, Fegan G, Chengo E, Odhiambo R, Bauni E, et al. Premature 
mortality in active convulsive epilepsy in rural Kenya: causes and associated 
factors. Neurology 2014;82(7):582–9. 
[7] Birbeck GL, Kalichi EM. Epilepsy prevalence in rural Zambia: a door-to-door 
survey. Tropical medicine & international health. TM & IH 2004;9(1):92–5. 
[8] Kaamugisha J, Feksi AT. Determining the prevalence of epilepsy in the semi-urban 
population of Nakuru, Kenya, comparing two independent methods not apparently 
used before in epilepsy studies. Neuroepidemiology 1988;7(3):115–21. 
[9] Cockerell OC, Eckle I, Goodridge DM, Sander JW, Shorvon SD. Epilepsy in a 
population of 6000 re-examined: secular trends in first attendance rates, 
prevalence, and prognosis. J Neurol Neurosurg Psychiatry 1995;58(5):570–6. 
[10] Vespa PM, Nuwer MR, Nenov V, Ronne-Engstrom E, Hovda DA, Bergsneider M, 
et al. Increased incidence and impact of nonconvulsive and convulsive seizures 
after traumatic brain injury as detected by continuous electroencephalographic 
monitoring. J Neurosurg 1999;91(5):750–60. 
[11] Snow RW, Williams RE, Rogers JE, Mung’ala VO, Peshu N. The prevalence of 
epilepsy among a rural Kenyan population. Its association with premature 
mortality. TropGeogrMed 1994;46:175–9. 
[12] Mung’ala Odera V, White S, Meehan R, Otieno GO, Njuguna P, Mturi N, Edwards T, 
Neville BG. Newton CRJC: Prevalence, Incidence and risk factors of epilepsy among 
older children in Kenya. Seizure 2008;17. 396 - 404. 
[13] Ngugi AK, Bottomley C, Kleinschmidt I, Wagner RG, Kakooza-Mwesige A, Ae- 
Ngibise K, Owusu-Agyei S, Masanja H, Kamuyu G, Odhiambo R, et al. Prevalence of 
active convulsive epilepsy in sub-Saharan Africa and associated risk factors: cross- 
sectional and case-control studies. Lancet Neurol 2013;12(3):253–63. 
[14] Scott JA, Bauni E, Moisi JC, Ojal J, Gatakaa H, Nyundo C, Molyneux CS, Kombe F, 
Tsofa B, Marsh K, et al. Profile: The Kilifi Health and Demographic Surveillance 
System (KHDSS). Int J Epidemiol 2012:1–8. 
[15] Kamuyu G, Bottomley C, Mageto J, Lowe B, Wilkins PP, Noh JC, Nutman TB, 
Ngugi AK, Odhiambo R, Wagner RG, et al. Exposure to multiple parasites is 
associated with the prevalence of active convulsive epilepsy in sub-saharan Africa. 
PLoS NeglTrop Dis 2014;8(5):e2908. 
[16] Edwards T, Scott AG, Munyoki G, MaO V, Chengo E, Bauni E, et al. Active 
convulsive elipepsy in a rural district of Kenya: A study of prevalence and possible 
risk factors. Lancet Neurol 2008;7:50–6. 
[17] Daniel WW. Biostatistics: a foundation for analysis in the health sciences. 7th 
Edition. John Wiley and Sons New York; 1999. 
[18] Lwanga SK, Lemeshow S. Sample size determination in health studies: a practical 
manual. World Health Organization Geneva; 1991. 
[19] Ngugi AK, Bottomley C, Chengo E, Kombe MZ, Kazungu M, Bauni E, Mbuba CK, 
Kleinschmidt I, Newton CR. The validation of a three-stage screening methodology 
for detecting active convulsive epilepsy in population-based studies in health and 
demographic surveillance systems. Emerg Themes Epidemiol 2012;9(1):8. 
[20] ILAE: guidelines for epidemiologic studies on epilepsy. Commission on 
epidemiology and prognosis, international league against epilepsy. Epilepsia 1993; 
34(4):592–6. 
[21] Thurman DJ, Beghi E, Begley CE, Berg AT, Buchhalter JR, Ding D, Hesdorffer DC, 
Hauser WA, Kazis L, Kobau R, et al. Standards for epidemiologic studies and 
surveillance of epilepsy. Epilepsia 2011;52:2–26. 
[22] MacDonald BK, Cockerell OC, Sander JW, Shorvon SD. The incidence and lifetime 
prevalence of neurological disorders in a prospective community-based study in 
the UK. Brain 2000;123(Pt 4):665–76. 
[23] Kariuki SM, Rockett K, Clark TG, Reyburn H, Agbenyega T, Taylor TE, et al. The 
genetic risk of acute seizures in African children with falciparum malaria. Epilepsia 
2013;54(6):990–1001. 
[24] Wang WZ, Wu JZ, Wang DS, Dai XY, Yang B, Wang TP, Yuan CL, Scott RA, 
Prilipko LL, de Boer HM, et al. The prevalence and treatment gap in epilepsy in 
China: an ILAE/IBE/WHO study. Neurology 2003;60(9):1544–5. 
[25] Beletsky V, Mirsattari SM. Epilepsy, mental health disorder, or both? Epilepsy Res 
Treatment 2012;2012:163731. 
[26] Cross JH, Jackson GD, Neville BG, Connelly A, Kirkham FJ, Boyd SG, et al. Early 
detection of abnormalities in partial epilepsy using magnetic resonance. Arch Dis 
Child 1993;69(1):104–9. 
[27] Buchhalter J. Treatment of childhood absence epilepsy-an evidence-based answer 
at last! Epilepsy currents.  Am Epilepsy Soc 2011;11(1):12–5. 
[28] Hamano S, Mochizuki M, Morikawa T. Phenobarbital-induced atypical absence 
seizure in benign childhood epilepsy with centrotemporal spikes. Seizure 2002;11 
(3):201–4. 
[29] Kessler SK, McGinnis E. A practical guide to treatment of childhood absence 
epilepsy. Pediatric Drugs 2019;21(1):15–24. 
[30] Engel J. ILAE classification of epilepsy syndromes. Epilepsy Res 2006;70(Suppl 1): 
S5–10. 
[31] Kariuki SM, Abubakar A, Kombe M, Kazungu M, Odhiambo R, Stein A, Newton C. 
Prevalence, risk factors and behavioural and emotional comorbidity of acute 
seizures in young Kenyan children: a population-based study. BMC Med 2018;16 
(1):35. 
S.M. Kariuki et al.                                                                                                                                                                                                                              
Downloaded for Anonymous User (n/a) at Aga Khan University Hospital from ClinicalKey.com by Elsevier on July 13, 
2021. For personal use only. No other uses without permission. Copyright ©2021. Elsevier Inc. All rights reserved.
